CCR9 interactions support ovarian cancer cell survival and resistance to cisplatin-induced apoptosis in a PI3K-dependent and FAK-independent fashion

BACKGROUND: Cisplatin is more often used to treat ovarian cancer (OvCa), which provides modest survival advantage primarily due to chemo-resistance and up regulated anti-apoptotic machineries in OvCa cells. Therefore, targeting the mechanisms responsible for cisplatin resistance in OvCa cell may imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Erica L, Singh, Rajesh, Johnson-Holiday, Crystal M, Grizzle, William E, Partridge, Edward E, Lillard, James W, Singh, Shailesh
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2914045/
https://www.ncbi.nlm.nih.gov/pubmed/20565782
http://dx.doi.org/10.1186/1757-2215-3-15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2914045/
https://www.ncbi.nlm.nih.gov/pubmed/20565782
http://dx.doi.org/10.1186/1757-2215-3-15

Ejemplares similares